ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report

BackgroundEntrectinib, a recently approved multikinase inhibitor indicated for advanced ROS1-positive non-small cell lung cancer (NSCLC), has demonstrated significant survival benefits in metastatic disease. However, it carries risks of severe cardiotoxicity. We report the successful management of e...

Full description

Saved in:
Bibliographic Details
Main Authors: Qi Yujuan, Ma Xiaozhong, Wu Zhenhua, Bai Yunpeng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2025.1626318/full
Tags: Add Tag
No Tags, Be the first to tag this record!